Curative Price To Sales Ratio vs Ev To Sales Analysis

CUBT Stock

USD 0.01 0.01 33.75%

Curative Biotechnology financial indicator trend analysis is way more than just evaluating Curative Biotechnology prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Curative Biotechnology is a good investment. Please check the relationship between Curative Biotechnology Price To Sales Ratio and its Ev To Sales accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Curative Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.

Price To Sales Ratio vs Ev To Sales

Price To Sales Ratio vs Ev To Sales Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Curative Biotechnology Price To Sales Ratio account and Ev To Sales. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Curative Biotechnology's Price To Sales Ratio and Ev To Sales is 0.84. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Ev To Sales in the same time period over historical financial statements of Curative Biotechnology, assuming nothing else is changed. The correlation between historical values of Curative Biotechnology's Price To Sales Ratio and Ev To Sales is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Curative Biotechnology are associated (or correlated) with its Ev To Sales. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ev To Sales has no effect on the direction of Price To Sales Ratio i.e., Curative Biotechnology's Price To Sales Ratio and Ev To Sales go up and down completely randomly.

Correlation Coefficient

0.84

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Curative Biotechnology stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Curative Biotechnology sales, a figure that is much harder to manipulate than other Curative Biotechnology multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Most indicators from Curative Biotechnology's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Curative Biotechnology current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Curative Biotechnology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Curative Stock please use our How to Invest in Curative Biotechnology guide.Enterprise Value is likely to gain to about 15.4 M in 2025, whereas Selling General Administrative is likely to drop slightly above 1.7 M in 2025.

Curative Biotechnology fundamental ratios Correlations

	Total Current Liabilities	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Net Receivables	Inventory	Total Current Assets	Common Stock	Property Plant Equipment	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Short Term Debt	Net Invested Capital	Short Long Term Debt	Net Working Capital	Capital Stock	Good Will
Total Current Liabilities		0.34	-0.81	-0.9	0.99	0.5	-0.72	0.17	-0.56	-0.18	0.82	0.95	-0.75	-0.28	0.58	0.95	0.92	0.85	0.92	0.45	0.95	-0.86	0.86	-0.9	-0.68	-0.02
Other Liab	0.34		-0.33	-0.35	0.32	-0.34	-0.39	0.2	-0.63	-0.35	0.37	0.32	-0.32	-0.21	0.16	0.25	0.33	0.4	0.35	0.26	0.32	-0.35	0.38	-0.22	-0.36	0.14
Net Tangible Assets	-0.81	-0.33		0.98	-0.78	-0.46	0.91	-0.34	0.62	0.16	-0.92	-0.86	0.52	0.7	-0.78	-0.62	-0.97	-0.89	-0.96	-0.82	-0.86	0.99	-0.95	0.71	0.89	-0.5
Retained Earnings	-0.9	-0.35	0.98		-0.88	-0.49	0.88	-0.28	0.62	0.18	-0.91	-0.92	0.61	0.59	-0.76	-0.75	-0.99	-0.93	-0.98	-0.72	-0.92	0.99	-0.96	0.81	0.85	-0.35
Accounts Payable	0.99	0.32	-0.78	-0.88		0.52	-0.67	0.07	-0.52	-0.16	0.77	0.91	-0.77	-0.31	0.58	0.93	0.9	0.83	0.89	0.46	0.91	-0.84	0.83	-0.94	-0.62	-0.09
Net Receivables	0.5	-0.34	-0.46	-0.49	0.52		-0.37	0.19	0.25	0.46	0.45	0.51	-0.4	-0.17	0.42	0.57	0.48	0.46	0.48	0.26	0.51	-0.46	0.39	-0.55	-0.38	-0.17
Inventory	-0.72	-0.39	0.91	0.88	-0.67	-0.37		-0.66	0.75	0.3	-0.97	-0.78	0.6	0.67	-0.51	-0.56	-0.85	-0.77	-0.87	-0.8	-0.78	0.9	-0.9	0.5	0.99	-0.46
Total Current Assets	0.17	0.2	-0.34	-0.28	0.07	0.19	-0.66		-0.43	-0.19	0.61	0.32	-0.32	-0.21	-0.1	0.17	0.23	0.24	0.32	0.3	0.32	-0.3	0.37	0.19	-0.71	0.29
Common Stock	-0.56	-0.63	0.62	0.62	-0.52	0.25	0.75	-0.43		0.67	-0.69	-0.55	0.51	0.48	-0.22	-0.38	-0.6	-0.54	-0.62	-0.57	-0.55	0.64	-0.69	0.32	0.71	-0.34
Property Plant Equipment	-0.18	-0.35	0.16	0.18	-0.16	0.46	0.3	-0.19	0.67		-0.23	-0.13	0.24	0.17	0.06	-0.08	-0.16	-0.18	-0.17	-0.19	-0.13	0.19	-0.23	0.04	0.26	-0.11
Total Assets	0.82	0.37	-0.92	-0.91	0.77	0.45	-0.97	0.61	-0.69	-0.23		0.9	-0.62	-0.54	0.54	0.7	0.91	0.81	0.94	0.7	0.9	-0.92	0.94	-0.58	-0.97	0.4
Short Long Term Debt Total	0.95	0.32	-0.86	-0.92	0.91	0.51	-0.78	0.32	-0.55	-0.13	0.9		-0.63	-0.27	0.62	0.9	0.94	0.86	0.96	0.46	1.0	-0.88	0.9	-0.78	-0.77	0.19
Other Current Liab	-0.75	-0.32	0.52	0.61	-0.77	-0.4	0.6	-0.32	0.51	0.24	-0.62	-0.63		0.17	-0.08	-0.75	-0.59	-0.58	-0.61	-0.3	-0.63	0.57	-0.67	0.63	0.55	0.3
Total Stockholder Equity	-0.28	-0.21	0.7	0.59	-0.31	-0.17	0.67	-0.21	0.48	0.17	-0.54	-0.27	0.17		-0.58	0.0	-0.57	-0.47	-0.52	-0.98	-0.27	0.67	-0.59	0.3	0.66	-0.62
Property Plant And Equipment Net	0.58	0.16	-0.78	-0.76	0.58	0.42	-0.51	-0.1	-0.22	0.06	0.54	0.62	-0.08	-0.58		0.4	0.76	0.79	0.71	0.63	0.62	-0.76	0.63	-0.67	-0.49	0.48
Net Debt	0.95	0.25	-0.62	-0.75	0.93	0.57	-0.56	0.17	-0.38	-0.08	0.7	0.9	-0.75	0.0	0.4		0.76	0.73	0.79	0.18	0.9	-0.68	0.7	-0.84	-0.53	-0.26
Non Current Assets Total	0.92	0.33	-0.97	-0.99	0.9	0.48	-0.85	0.23	-0.6	-0.16	0.91	0.94	-0.59	-0.57	0.76	0.76		0.9	0.99	0.72	0.94	-0.98	0.96	-0.82	-0.82	0.35
Common Stock Shares Outstanding	0.85	0.4	-0.89	-0.93	0.83	0.46	-0.77	0.24	-0.54	-0.18	0.81	0.86	-0.58	-0.47	0.79	0.73	0.9		0.89	0.59	0.86	-0.91	0.86	-0.8	-0.73	0.26
Other Stockholder Equity	0.92	0.35	-0.96	-0.98	0.89	0.48	-0.87	0.32	-0.62	-0.17	0.94	0.96	-0.61	-0.52	0.71	0.79	0.99	0.89		0.68	0.96	-0.97	0.97	-0.78	-0.86	0.36
Total Liab	0.45	0.26	-0.82	-0.72	0.46	0.26	-0.8	0.3	-0.57	-0.19	0.7	0.46	-0.3	-0.98	0.63	0.18	0.72	0.59	0.68		0.46	-0.8	0.74	-0.4	-0.79	0.62
Short Term Debt	0.95	0.32	-0.86	-0.92	0.91	0.51	-0.78	0.32	-0.55	-0.13	0.9	1.0	-0.63	-0.27	0.62	0.9	0.94	0.86	0.96	0.46		-0.88	0.9	-0.78	-0.77	0.19
Net Invested Capital	-0.86	-0.35	0.99	0.99	-0.84	-0.46	0.9	-0.3	0.64	0.19	-0.92	-0.88	0.57	0.67	-0.76	-0.68	-0.98	-0.91	-0.97	-0.8	-0.88		-0.96	0.77	0.87	-0.42
Short Long Term Debt	0.86	0.38	-0.95	-0.96	0.83	0.39	-0.9	0.37	-0.69	-0.23	0.94	0.9	-0.67	-0.59	0.63	0.7	0.96	0.86	0.97	0.74	0.9	-0.96		-0.69	-0.89	0.42
Net Working Capital	-0.9	-0.22	0.71	0.81	-0.94	-0.55	0.5	0.19	0.32	0.04	-0.58	-0.78	0.63	0.3	-0.67	-0.84	-0.82	-0.8	-0.78	-0.4	-0.78	0.77	-0.69		0.43	0.14
Capital Stock	-0.68	-0.36	0.89	0.85	-0.62	-0.38	0.99	-0.71	0.71	0.26	-0.97	-0.77	0.55	0.66	-0.49	-0.53	-0.82	-0.73	-0.86	-0.79	-0.77	0.87	-0.89	0.43		-0.5
Good Will	-0.02	0.14	-0.5	-0.35	-0.09	-0.17	-0.46	0.29	-0.34	-0.11	0.4	0.19	0.3	-0.62	0.48	-0.26	0.35	0.26	0.36	0.62	0.19	-0.42	0.42	0.14	-0.5

Click cells to compare fundamentals

Curative Biotechnology Account Relationship Matchups

Curative Biotechnology fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Current Liabilities	665.0K	730.3K	4.5M	5.7M	6.6M	6.9M
Retained Earnings	(8.1M)	(26.9M)	(32.6M)	(38.2M)	(34.4M)	(32.7M)
Accounts Payable	97.83	726.9	3.4M	3.5M	4.0M	4.2M
Total Current Assets	2.1M	753.9K	68.7K	604.5K	695.1K	369.0K
Common Stock	83.0	143.0	57.9K	90.3K	81.3K	77.2K
Total Assets	2.3M	2.4M	2.1M	2.6M	3.0M	3.1M
Short Long Term Debt Total	124.8	559.8K	1.1M	2.3M	2.6M	2.7M
Other Current Liab	535.6K	(124.8)	105.1K	729.6K	(17.2K)	0.0
Total Stockholder Equity	(4.5M)	(16.4M)	(20.5M)	(3.1M)	(2.8M)	(3.0M)
Property Plant And Equipment Net	2.3K	6.7K	6.3K	5.8K	6.7K	4.9K
Net Debt	399.2K	(670.3K)	1.0M	2.2M	2.5M	2.7M
Non Current Assets Total	142.6K	1.7M	2.0M	2.0M	2.3M	2.4M
Common Stock Shares Outstanding	326.7M	501.0M	572.0M	662.2M	761.5M	461.0M
Liabilities And Stockholders Equity	2.3M	2.4M	2.1M	2.6M	3.0M	3.1M
Other Stockholder Equity	9.7M	28.6M	30.0M	35.0M	40.2M	42.3M
Total Liab	6.8M	18.8M	22.6M	5.7M	6.6M	7.8M
Short Term Debt	124.8	559.8K	1.1M	2.3M	2.6M	2.7M
Cash	160.6K	670.3K	58.7K	56.4K	64.9K	61.6K
Net Invested Capital	(360.8K)	(4.0M)	(16.4M)	(19.5M)	(17.5M)	(16.6M)
Net Working Capital	(397.1K)	1.5M	23.6K	(4.4M)	(4.0M)	(3.8M)
Intangible Assets	140.3	1.6K	1.5M	1.4M	1.6M	1.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Curative Stock Analysis

When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC